Small molecule RNase inhibitors and methods of use

US9517230B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9517230-B2
Application numberUS-201514744205-A
CountryUS
Kind codeB2
Filing dateJun 19, 2015
Priority dateJan 26, 2011
Publication dateDec 13, 2016
Grant dateDec 13, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of treating, reducing, or inhibiting a bacterial infection in a subject, comprising administering to the subject an effective amount of an RNase inhibitor of the following structure: or a pharmaceutically acceptable salt or prodrug thereof, wherein the bacterial infection is a Staphylococcus infection. 2. The method of claim 1 , wherein the Staphylococcus infection is a Staphylococcus aureus infection. 3. The method of claim 2 , wherein the Staphylococcus aureus infection is a drug-resistant Staphylococcus aureus infection. 4. The method of claim 2 , wherein the Staphylococcus aureus infection is a biofilm-associated Staphylococcus aureus infection. 5. The method of claim 1 , wherein the RNase inhibitor is a RnpA inhibitor. 6. The method of claim 1 , further comprising administering a second compound, wherein the second compound is an antibacterial compound. 7. A method of inhibiting a bacterial ribonuclease comprising contacting the bacterial ribonuclease with an effective amount of an RNase inhibitor of the following structure: or a pharmaceutically acceptable salt or prodrug thereof, wherein the bacterial ribonuclease is Staphylococcus aureus RNase P. 8. The method of claim 7 , wherein the bacterial ribonuclease is RnpA. 9. The method of claim 7 , wherein the contacting occurs in vivo. 10. The method of claim 7 , wherein the contacting occurs in vitro.

Assignees

Inventors

Classifications

  • A61K31/427Primary

    not condensed and containing further heterocyclic rings · CPC title

  • Ribonucleases (RNAses); Deoxyribonucleases (DNAses) · CPC title

  • involving esterase · CPC title

  • Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

  • Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9517230B2 cover?
Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease.
Who is the assignee on this patent?
Univ Rochester, Univ Nebraska, Temple University—Of the Commonwealth System of Higher Education
What technology area does this patent fall under?
Primary CPC classification A61K31/427. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).